Camrelizumab、Rivoceranib + Camrelizumab
Phase 2CompletedDevelopment Stage
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Sep 1, 2022 → Nov 15, 2024
About Camrelizumab、Rivoceranib + Camrelizumab
Camrelizumab、Rivoceranib + Camrelizumab is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation. The current trial status is completed. This product is registered under clinical trial identifier NCT05367687. Target conditions include Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05367687 | Phase 2 | Completed |
Competing Products
9 competing products in Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Trastuzumab Emtansine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Fluad + Saline | Novartis | Approved | 85 |
| Letrozole | Novartis | Approved | 85 |
| Biomarker Testing | Roche | Pre-clinical | 23 |
| Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib | Pfizer | Phase 2 | 51 |
| Elinzanetant (BAY3427080) + Placebo | Bayer | Phase 3 | 74 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6) | Adlai Nortye | Phase 1 | 25 |
| Pembrolizumab, Eftilagimod alfa | Immutep | Phase 2 | 44 |